Evidence map›Paper›PMID 35763642›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Potential of Apolipoprotein A1 (ApoA1) for Detecting Liver Cirrhosis and Hepatocellular Carcinoma.

Nur Signa Aini Gumilas, Ika Murti Harini, Dwi Arini Ernawati, Vitasari Indriani, Dody Novrial, Dhadhang Wahyu Kurniawan

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Translational cancer research · 2024
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nur Signa Aini GumilasDepartment of Histology, Faculty of Medicine, Universitas Jenderal Soedirman, Indonesia.ORCID 0000-0002-9904-2133
Ika Murti HariniDepartment of Histology, Faculty of Medicine, Universitas Jenderal Soedirman, Indonesia.ORCID 0000-0002-4465-7878
Dwi Arini ErnawatiDepartment of Public Health, Faculty of Medicine, Universitas Jenderal Soedirman, Indonesia.ORCID 0000-0002-4186-1654
Vitasari IndrianiDepartment of Clinical Pathology, Faculty of Medicine, Universitas Jenderal Soedirman, Indonesia.ORCID 0000-0001-8563-1781
Dody NovrialDepartment of Anatomical Pathology, Faculty of Medicine, Universitas Jenderal Soedirman, Indonesia.ORCID 0000-0002-3807-852X
Dhadhang Wahyu KurniawanDepartment of Pharmacy, Faculty of Health Sciences, Universitas Jenderal Soedirman, Indonesia.ORCID 0000-0003-4843-3756
Jenderal Soedirman University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLiver cirrhosis and hepatocellular carcinoma (HCC) are chronic liver diseases that can cause serious health problems. Meanwhile, the methods used to detect liver cirrhosis and HCC are limited. Apolipoprotein A1 (ApoA1) is a protein that makes up high-density lipoprotein (HDL), which plays a role in liver cirrhosis and HCC, and can be used as a biomarker. This study aims to determine the ability of ApoA1 to detect and differentiate liver cirrhosis and hepatocellular carcinoma.

methodsThis cross-sectional study was conducted on 47 patients with liver cirrhosis and HCC at Margono Soekarjo Regional General Hospital, Purwokerto, Indonesia. This study also involved 33 healthy participants from blood donors at the Blood Transfusion Unit, Indonesian Red Cross, Banyumas. Serum ApoA1 levels were analyzed by ELISA method. Receiver Operating Characteristics (ROC) were used to evaluate the diagnostic power of ApoA1 and differentiate between cirrhotic, HCC, and healthy patients. Multivariate binary logistic regression test to determine the most influential variables on the incidence of cirrhosis, HCC, and health.

resultsApoA1 was able to differentiate cirrhosis from HCC, cirrhosis from healthy and HCC from healthy, with sensitivity 56.7%, 86.7%, 70.6%, specificity 70.6%, 93.9%, 84.9%, respectively, and AUC 68.5%, 92.6%, 75.0%. AFP (p = 0.002, OR 1.004) and bilirubin (p = 0.021, OR 1.259) were variables that contributed to cirrhosis - HCC. Age (p = 0.011, OR 0.766) and AST (p = 0.003, OR 0.834) are variables that play a role in health - cirrhosis. ALT (p = 0.024, OR 0.965) and PT (p = 0.004, OR 0.253) are variables that play a role in healthy - HCC.

conclusionApoA1 was best for detecting healthy from cirrhosis, followed by healthy from HCC and cirrhosis from HCC. ApoA1 is not the primary variable determining the incidence of cirrhosis - HCC, healthy - HCC, and healthy - HCC.

Indexed as

Carcinoma, HepatocellularLiver Neoplasmsalpha-FetoproteinsApolipoprotein A-IBiomarkers, TumorCross-Sectional StudiesHumansLiver Cirrhosisalpha-FetoproteinsAPOA1 protein, humanApolipoprotein A-IBiomarkers, TumorApolipoprotein A1Biomarkerhepatic cirrhosisHepatocellular carcinoma

Identifiers

PMID35763642
PMCPMC9587809
OpenAlexW4283656877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.